Further Funding. 19.1 Save as provided in Clause 17, the Company undertakes that it will not, without the prior written consent of the Trust (such consent not to be unreasonably withheld, delayed or conditioned), accept any further funding to complete the Phase II trial of SMT 19969 by way of loan, grant or other funding the conditions of which would materially prejudice the Trust’s position under this Agreement with respect to its share of Net Revenues or its rights to become the Exploiting Party set forth in Clause 16. For clarity the Company is not restricted from raising general working capital.
Appears in 2 contracts
Sources: Translation Award Funding Agreement (Summit Therapeutics PLC), Translation Award Funding Agreement (Summit Corp PLC)